Would you treat a completely resected Stage IA NSCLC EGFR exon 19 with adjuvant osimertinib alone omitting chemotherapy?  

More is not always better. Maximum therapy does not equal optimal therapy. With a 3-year DFS estimated at 95% (95% CI: 91%, 98% - Jung et al., PMID 37308037), the benefit-risk profile of any adjuvant systemic therapy is likely unfavorable, including for well-tolerated drugs like osimertinib. In the ...